Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m (Jwarner moved page Caplacizumab to Caplacizumab (ALX-0081)) |
(No difference)
| |
Revision as of 16:50, 18 November 2017
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Preliminary data
Thrombotic thrombocytopenic purpura
- Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. link to original article PubMed